Finally, to assess the enhancer activity of the FSCN1 gene in NEPC, we took advantage of the genome-wide H3K27 acetylation analyses performed by Baca et al. [34], in NEPC and prostate adenocarcinoma (PRAD) LuCap patient-derived xenografts (PDXs). Here, FSCN1 is linked to prostate adenocarcinoma.